INNOGEN-B (02591) Pulls Back Over 13% After 50% Rally in Two Weeks, Officially Added to Stock Connect Today

Stock News12-08 10:24

INNOGEN-B (02591) retreated more than 13%, following a 50% surge over the past two weeks. At the time of writing, the stock fell 13.64% to HK$38, with a turnover of HK$30.31 million.

The Shanghai and Shenzhen Stock Exchanges announced that INNOGEN-B has been added to the Stock Connect program effective December 8, 2025, as part of the Hang Seng Composite MidCap Index constituent adjustment.

Additionally, INNOGEN-B disclosed that its self-developed ultra-long-acting GLP-1 receptor agonist, Esupaglutide α (Yinuoqing®), has been officially included in the 2025 National Reimbursement Drug List (NRDL). The inclusion will take effect concurrently with the updated list starting January 1, 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123349506?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123349506","market":"us","top_or_hot":-1,"title":"INNOGEN-B (02591) Pulls Back Over 13% After 50% Rally in Two Weeks, Officially Added to Stock Connect Today","media":"Stock News","content":"<p>INNOGEN-B (02591) retreated more than 13%, following a 50% surge over the past two weeks. At the time of writing, the stock fell 13.64% to HK$38, with a turnover of HK$30.31 million.</p>\n<p>The Shanghai and Shenzhen Stock Exchanges announced that INNOGEN-B has been added to the Stock Connect program effective December 8, 2025, as part of the Hang Seng Composite MidCap Index constituent adjustment.</p>\n<p>Additionally, INNOGEN-B disclosed that its self-developed ultra-long-acting GLP-1 receptor agonist, Esupaglutide α (Yinuoqing®), has been officially included in the 2025 National Reimbursement Drug List (NRDL). The inclusion will take effect concurrently with the updated list starting January 1, 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOGEN-B (02591) Pulls Back Over 13% After 50% Rally in Two Weeks, Officially Added to Stock Connect Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOGEN-B (02591) Pulls Back Over 13% After 50% Rally in Two Weeks, Officially Added to Stock Connect Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 10:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOGEN-B (02591) retreated more than 13%, following a 50% surge over the past two weeks. At the time of writing, the stock fell 13.64% to HK$38, with a turnover of HK$30.31 million.</p>\n<p>The Shanghai and Shenzhen Stock Exchanges announced that INNOGEN-B has been added to the Stock Connect program effective December 8, 2025, as part of the Hang Seng Composite MidCap Index constituent adjustment.</p>\n<p>Additionally, INNOGEN-B disclosed that its self-developed ultra-long-acting GLP-1 receptor agonist, Esupaglutide α (Yinuoqing®), has been officially included in the 2025 National Reimbursement Drug List (NRDL). The inclusion will take effect concurrently with the updated list starting January 1, 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1123349506","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123349506","pubTimestamp":1765160654,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOGEN-B (02591) retreated more than 13%, following a 50% surge over the past two weeks. At the time of writing, the stock fell 13.64% to HK$38, with a turnover of HK$30.31 million. The Shanghai and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02591":"银诺医药－Ｂ"},"translate_title":"英诺健-B(02591)两周大涨50%后回调超13%今日正式纳入沪股通","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"INNOGEN-B (02591) retreated more than 13%, following a 50% surge over the past two weeks. At the time of writing, the stock fell 13.64% to HK$38, with a turnover of HK$30.31 million.\nThe Shanghai and Shenzhen Stock Exchanges announced that INNOGEN-B has been added to the Stock Connect program effective December 8, 2025, as part of the Hang Seng Composite MidCap Index constituent adjustment.\nAdditionally, INNOGEN-B disclosed that its self-developed ultra-long-acting GLP-1 receptor agonist, Esupaglutide α (Yinuoqing®), has been officially included in the 2025 National Reimbursement Drug List (NRDL). The inclusion will take effect concurrently with the updated list starting January 1, 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123349506","isCrawlerRequest":true}